Patent: 9,982,302
✉ Email this page to a colleague
Summary for Patent: 9,982,302
Title: | Biological markers and methods for predicting response to B-cell antagonists |
Abstract: | Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided. |
Inventor(s): | Behrens; Timothy W. (Burlingame, CA), Owczarczyk; Kasia (London, GB), Townsend; Michael J. (San Jose, CA) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 15/019,615 |
Patent Claims: | see list of patent claims |
Details for Patent 9,982,302
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-02-28 |
Bristol-myers Squibb Company | ORENCIA | abatacept | For Injection | 125118 | 12/23/2005 | ⤷ Try a Trial | 2031-02-28 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 07/29/2011 | ⤷ Try a Trial | 2031-02-28 |
Bristol-myers Squibb Company | ORENCIA | abatacept | Injection | 125118 | 06/07/2016 | ⤷ Try a Trial | 2031-02-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |